コメンタリー

(English) Catenion’s ASAP for Bio-pharma

申し訳ありません、このコンテンツはただ今 アメリカ英語 のみです。

この記事をダウンロードする

Risk Profiles of Corporate Portfolio Strategies

The current meltdown of some segments of the global banking system can be seen as a direct result of three systemic weaknesses in the way that many financial services companies operated in a largely deregulated financial system during the last three decades. In this commentary we discuss how a thorough understanding of portfolio risk profiles can help companies design more sustainable strategies. We explore a new valuation methodology, and discuss a number of examples and case studies. 

この記事をダウンロードする

Zero Base Pharmaceutical R&D — A Thought Experiment to Address the Pharmaceutical Research Crisis

What we mean by “Zero Base R&D”. The concept of zero based budgeting was originally introduced to help managers of private and public organisations systematically question the utility of each and every activity they plan to spend money on in the next fiscal period.

この記事をダウンロードする

Recombinant Innovation Management (RIM) — How to Stimulate Breakthrough Innovation within Large R&D Organisations

Pharmaceutical R&D is in a state of crisis: productivity is declining both in terms of output per spending as well as total output, while patent expirations threaten many successful product franchises within the next years. The main issue is that impressive advances in process productivity have not translated into more novel products addressing unmet needs.

この記事をダウンロードする

Recombinant Portfolio Management — Recognising and Enabling Innovation

Portfolio management has become standard practice in pharmaceutical R&D over the last decade. Most companies have implemented processes and systems with varying degrees of sophistication and rigour across the entire R&D value chain from early discovery to late development, both for internal opportunities and as part of due diligence and licensing activities for external opportunities.

この記事をダウンロードする

The Challenge for Japan’s Pharmaceutical Top Twenty

Simply copying the business models of the West will not do for Japanese companies to fulfill the Ministry’s vision, except through sheer luck. To many observers, the country’s industrial genius lies in imitating and improving on Western models, as exemplified by the success stories of the Japanese electronics, ship–building, machine tool and car industries. We show in this Commentary that establishing sustainable positions of competitiveness in the global pharmaceutical industry will require more than incremental innovation.

この記事をダウンロードする

Elements of a Winning R&D Strategy

R&D strategies come in different shapes and sizes. Some companies focus their efforts on therapeutic areas or indications, some on drug formats, some rely on scientific excellence and breakthrough innovation while others are obsessed with productivity and efficiency. What are the winning elements of R&D strategies?

この記事をダウンロードする